{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:50:07Z","timestamp":1792713007911,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background and purpose<\/jats:title>\n                    <jats:p>No research currently exists on the role of the accessory parotid gland (APG) in nasopharyngeal carcinoma (NPC). We thereby aimed to assess the effects of APG on the dosimetry of the parotid glands (PGs) during NPC radiotherapy and evaluate its predictive value for late xerostomia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>The clinical data of 32 NPC patients with radiological evidence of the APG treated at Sun Yat-sen Memorial Hospital between November 2020 and February 2021 were retrospectively reviewed. Clinically approved treatment plans consisted of only the PGs as an organ at risk (OAR) (Plan1), while Plan2 was designed by considering the APG as a single organ at risk (OAR). The APG on Plan1 was delineated, and dose\u2013volume parameters of the PGs alone (PG-only) and of the combined structure (PG+APG) were analyzed in both plans. The association of such dosimetric parameters in Plan1 with xerostomia at 6\u20139 months post-radiotherapy was further explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty APGs were found, with a mean volume of 3.3 \u00b1 0.2 ml. Significant differences were found in all dosimetric parameters between Plan1 and Plan2. The mean dose and percentage of OAR volumes receiving more than 30 Gy significantly reduced in Plan1 itself (PG-only vs. PG+APG, 39.55 \u00b1 0.83 Gy vs. 37.71 \u00b1 0.75 Gy, and 62.00 \u00b1 2.00% vs. 57.41 \u00b1 1.56%, respectively; p &amp;lt; 001) and reduced further in Plan2 (PG+APG, 36.40 \u00b1 0.74 Gy, and 55.54 \u00b1 1.61%, respectively; p &amp;lt; 0.001). Three additional patients met the dose constraint in Plan1, which increased to seven in Plan2. With APG included, the predictive power of the dosimetric parameters for xerostomia tended to improve, although no significant differences were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>APG is anatomically similar to the PGs. Our findings suggest the potential benefits of treating the APG and PGs as a single OAR during radiotherapy (RT) of NPC by improving PG sparing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2022.958961","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:53:30Z","timestamp":1668128010000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Contouring the accessory parotid gland and major parotid glands as a single organ at risk during nasopharyngeal carcinoma radiotherapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Xin-Ling","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Tian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Shu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Min","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.04.021","article-title":"Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer","volume":"69","author":"Jellema","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-03067-y","article-title":"Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion","volume":"146","author":"Liao","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20150635","article-title":"A split-parotid delineation approach for dose optimization in volumetric modulated arc therapy for nasopharyngeal carcinoma patients with parapharyngeal space invasion and level IIa cervical lymph node involvements","volume":"89","author":"Xiao","year":"2016","journal-title":"Br J Radiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3747\/co.20.1485","article-title":"Superficial parotid lobe-sparing delineation approach: a better method of dose optimization to protect the parotid gland in intensity-modulated radiotherapy for nasopharyngeal carcinoma","volume":"20","author":"Zhang","year":"2013","journal-title":"Curr Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"305ra147","DOI":"10.1126\/scitranslmed.aac4441","article-title":"Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer","volume":"7","author":"van Luijk","year":"2015","journal-title":"Sci Transl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(77)90049-4","article-title":"The human accessory parotid gland: its incidence, nature, and significance","volume":"43","author":"Frommer","year":"1977","journal-title":"Oral surgery Oral medicine Oral Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ar.1092360319","article-title":"Incidence and histology of human accessory parotid glands","volume":"236","author":"Toh","year":"1993","journal-title":"Anat Rec"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150212","article-title":"Role of the accessory parotid gland in the etiology of parotitis: Statistical analysis of sialographic features","volume":"11","author":"Zhu","year":"2016","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2017.10.032","article-title":"International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma","volume":"126","author":"Lee","year":"2018","journal-title":"Radiotherapy Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.2540","article-title":"International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma","volume":"105","author":"Lee","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/153303461000900308","article-title":"Comparison of intensity-modulated radiotherapy using helical tomotherapy and segmental multileaf collimator-based techniques for nasopharyngeal carcinoma: dosimetric analysis incorporating quality assurance guidelines from RTOG 0225","volume":"9","author":"Chen","year":"2010","journal-title":"Technol Cancer Res Treat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70303-5","article-title":"Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00060-c","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1053-4296(03)00033-x","article-title":"How should we measure and report radiotherapy-induced xerostomia","volume":"13","author":"Eisbruch","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/scs.0000000000006092","article-title":"The accessory parotid gland and its clinical significance","volume":"31","author":"Rosa","year":"2020","journal-title":"J Craniofac Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0184633","DOI":"10.1371\/journal.pone.0184633","article-title":"The accessory parotid gland and facial process of the parotid gland on computed tomography","volume":"12","author":"Ahn","year":"2017","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00276-020-02483-x","article-title":"Description and relationships of the parotid gland levels proposed by the European salivary gland society staging system: an anatomical study","volume":"42","author":"Pujol-Olmo","year":"2020","journal-title":"Surg Radiol Anat"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjaa361","article-title":"The aging parotid gland: A longitudinal volumetric study and implications for treatment","volume":"41","author":"Tower","year":"2021","journal-title":"Aesthet Surg J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(99)00247-3","article-title":"Biology, physics. dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer","volume":"45","author":"Eisbruch","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.radonc.2020.06.016","article-title":"Saliva electrolyte analysis and xerostomia-related quality of life in nasopharyngeal carcinoma patients following intensity-modulated radiation therapy","volume":"150","author":"Lan","year":"2020","journal-title":"Radiother Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26634","article-title":"Durability of the parotid-sparing effect of intensity-modulated radiotherapy (IMRT) in early stage nasopharyngeal carcinoma: A 15-year follow-up of a randomized prospective study of IMRT versus two-dimensional radiotherapy","volume":"43","author":"Poon","year":"2021","journal-title":"Head Neck"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1038\/s41598-019-40228-y","article-title":"Dose\/Volume histogram patterns in salivary gland subvolumes influence xerostomia injury and recovery","volume":"9","author":"Han","year":"2019","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/0284186x.2017.1324209","article-title":"Parotid gland mean dose as a xerostomia predictor in low-dose domains","volume":"56","author":"Gabry\u015b","year":"2017","journal-title":"Acta Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.05.023","article-title":"Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer - a prospective cohort analysis","volume":"138","author":"Sommat","year":"2019","journal-title":"Radiother Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203308","article-title":"Prognostic nomogram of xerostomia for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy","volume":"12","author":"Xin-Bin","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-012-9445-6","article-title":"Risk model and nomogram for dysphagia and xerostomia prediction in head and neck cancer patients treated by radiotherapy and\/or chemotherapy","volume":"28","author":"Teguh","year":"2013","journal-title":"Dysphagia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.009","article-title":"Biology, physics. a deep learning model for predicting xerostomia due to radiation therapy for head and neck squamous cell carcinoma in the RTOG 0522 clinical trial","volume":"105","author":"Men","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.08.003","article-title":"Geometric image biomarker changes of the parotid gland are associated with late xerostomia","volume":"99","author":"van Dijk","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.958961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:53:32Z","timestamp":1668128012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.958961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":31,"alternative-id":["10.3389\/fonc.2022.958961"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.958961","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"article-number":"958961"}}